This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Org. Chem. 2021, 17, 2812–2821, doi:10.3762/bjoc.17.192
Graphical Abstract
Scheme 1: Synthetic route for the preparation of L1-M, L2-M and L3-M complexes.
Figure 1: Main geometrical features and the relative energies (in kcal·mol–1) of (A) ligand L1, (B) nickel- a...
Figure 2: Main geometrical features and the relative energies (in kcal mol–1) of (A) ligand L3, (B) nickel- a...
Beilstein J. Org. Chem. 2013, 9, 2422–2433, doi:10.3762/bjoc.9.280
Figure 1: Chiral gold(I) complexes employed in 1,3-DC involving azomethine ylides.
Scheme 1: 1,3-DC of azlactone 5a and NPM.
Scheme 2: General 1,3-DC between azlactones 5 with maleimides.
Scheme 3: Formation of the amide 8aa.
Figure 2: Positive non-linear effects (NLE) observed in 1,3-DC of azlactone 7aa and NPM.
Figure 3: Main geometrical features and relative Gibbs free energies (in kcal mol−1 at 298 K) of complexes [(S...
Figure 4: Main geometrical features and relative Gibbs free energies (in kcal mol−1) of the less energetic tr...
Scheme 4: Reaction Gibbs free energy associated with the 1,3-DC of 5aa and NPM catalyzed by (Sa)-Binap gold d...
Scheme 5: ΔG calculation for the recovery of the catalytic active species.
Scheme 6: 1,3-DC of azlactone 10 and tert-butyl acrylate.
Figure 5: (A) Schematic representation of the model gold(I) ylides. (B) HOMO of the ylides and expansion orbi...
Figure 6: Main geometrical features and relative Gibbs free energies (in kcal mol−1 at 298 K) of complexes [{(...
Figure 7: Main geometrical features and relative Gibbs free energies (in kcal mol−1) of the less energetic tr...
Scheme 7: Reduction of heterocycle 7aa under different conditions.
Scheme 8: Double 1,3-DC to give polycycle 15.
Scheme 9: Reaction between 7aa and nitrostyrene.
Beilstein J. Org. Chem. 2011, 7, 988–996, doi:10.3762/bjoc.7.111
Figure 1: More active GSK HCV inhibitors.
Scheme 1: Retrosynthetic analysis of antiviral structures.
Figure 2: Chiral phosphoramidites tested in this study.
Scheme 2: Optimization of the reaction conditions for the synthesis of the key intermediate 5b.
Scheme 3: Preparation of the enantiomerically enriched 5b.
Scheme 4: Total synthesis of antiviral agent 2b.
Figure 3: Gibbs activation energy and main geometrical features of the computed ylide and transition structur...